Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab biosimilar - Biocad

Next Previous
X
Search
Drug Profile

Trastuzumab biosimilar - Biocad

Alternative Names: BCD-022; HERtiCAD

Latest Information Update: 22 Jun 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocad
  • Developer Biocad; SPH-BIOCAD
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Gastric cancer; HER2 positive breast cancer

Most Recent Events

  • 07 Oct 2016 Efficacy and safety data from a phase III trial in Breast cancer presented at the 41st European Society for Medical Oncology Congress (ESMO - 2016)
  • 01 Oct 2016 Biocad completes a phase III trial in Her2 positive Breast cancer (Combination therapy, First-line therapy, Metastatic disease) in Russia, India, Ukraine and Belarus (IV) (NCT01764022)
  • 20 Jan 2016 Registered for Breast cancer (Combination therapy, First-line therapy, Metastatic disease) in Sri Lanka (IV) after January 2016

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top